226 related articles for article (PubMed ID: 18000938)
1. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.
Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938
[TBL] [Abstract][Full Text] [Related]
2. Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.
Tell V; Holzer M; Herrmann L; Mahmoud KA; Schächtele C; Totzke F; Hilgeroth A
Bioorg Med Chem Lett; 2012 Nov; 22(22):6914-8. PubMed ID: 23039927
[TBL] [Abstract][Full Text] [Related]
3. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
4. Approaches to a multitargeting drug development: first profiled 3- ethoxycarbonyl-1-aza-9-oxafluorenes representing a perspective compound class targeting Alzheimer disease relevant kinases CDK1, CDK5 and GSK-3β.
Hilgeroth A; Tell V; Kramer S; Totzke F; Schachtele C
Med Chem; 2014; 10(1):90-7. PubMed ID: 23477782
[TBL] [Abstract][Full Text] [Related]
5. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometry-based method to analyze the change in Tau phosphorylation in a hGSK-3beta and hTau over-expressing EcR-293 cell line.
Kurko D; Boros A; Dezso P; Urbányi Z; Sárvári M; Nagy J; Szombathelyi Z; Szendrei GI
Neurochem Int; 2006 Apr; 48(5):374-82. PubMed ID: 16420965
[TBL] [Abstract][Full Text] [Related]
7. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
Koh SH; Noh MY; Kim SH
Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ
J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661
[TBL] [Abstract][Full Text] [Related]
10. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease.
Sze CI; Su M; Pugazhenthi S; Jambal P; Hsu LJ; Heath J; Schultz L; Chang NS
J Biol Chem; 2004 Jul; 279(29):30498-506. PubMed ID: 15126504
[TBL] [Abstract][Full Text] [Related]
12. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
Leost M; Schultz C; Link A; Wu YZ; Biernat J; Mandelkow EM; Bibb JA; Snyder GL; Greengard P; Zaharevitz DW; Gussio R; Senderowicz AM; Sausville EA; Kunick C; Meijer L
Eur J Biochem; 2000 Oct; 267(19):5983-94. PubMed ID: 10998059
[TBL] [Abstract][Full Text] [Related]
13. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
14. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation.
Resende R; Ferreiro E; Pereira C; Oliveira CR
J Neurosci Res; 2008 Jul; 86(9):2091-9. PubMed ID: 18335524
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
16. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
Imahori K; Uchida T
J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
[TBL] [Abstract][Full Text] [Related]
17. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
[TBL] [Abstract][Full Text] [Related]
18. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation.
Sahara N; Murayama M; Lee B; Park JM; Lagalwar S; Binder LI; Takashima A
Eur J Neurosci; 2008 Jun; 27(11):2897-906. PubMed ID: 18540881
[TBL] [Abstract][Full Text] [Related]
19. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
Takashima A
J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
[TBL] [Abstract][Full Text] [Related]
20. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.
Liu F; Iqbal K; Grundke-Iqbal I; Gong CX
FEBS Lett; 2002 Oct; 530(1-3):209-14. PubMed ID: 12387894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]